Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287229
Status:
RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-02-23
Brief Title:
Phase IbII Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With RelapsedRefractory RR and Newly Diagnosed B-cell Acute Lymphocytic Leukemia ALL Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomabHCVAD-inotuzumab-blinatumomab
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2023-0627
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None